RxDoctor Payments Data

David Espino, MD

Geriatric Medicine · San Antonio, TXNPI 1710094701

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.3% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Amgen at 25.1% of the total. Among geriatric medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,606in general payments, 2019–2025

Across 22 payments — averaging $118.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$653
  • Neurocrine Biosciences, Inc.$513
  • Teva Pharmaceuticals USA, Inc.$513
  • Acadia Pharmaceuticals Inc$212
  • Lilly USA, LLC$125
  • Abbott$125
  • plus $464 from 4 others

What the payments were for

  • Consulting fees$1757%
  • Food & beverage$2,43193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,606 in reported general payments places this provider in the 90th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$15,444
Medicare patients
72
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab37$67,427
Esomeprazole Magnesium175$41,278
BriviactBrivaracetam25$25,175
Rufinamide14$22,339
Budesonide55$21,837
LinzessLinaclotide41$19,127
Pantoprazole Sodium31$12,089
EliquisApixaban22$11,264
Sucralfate33$8,761
Levalbuterol Hcl33$4,795
SynthroidLevothyroxine Sodium165$4,725
Acetylcysteine11$4,280
Lacosamide75$3,883
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate71$3,424
Levetiracetam106$3,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$653$67,42737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →